Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

COVID-19 Consortium MOU

9 Apr 2020 07:00

RNS Number : 2892J
Omega Diagnostics Group PLC
09 April 2020
 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Memorandum of Understanding

COVID-19 Consortium

 

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing announces that it has signed a Memorandum of Understanding ("MOU") with three other companies from across the UK, in conjunction with the University of Oxford to form the UK Rapid Test Consortium ("UK-RTC") in order to jointly develop and manufacture a COVID-19 Point of Care antibody test as part of the Government's five pillar national testing strategy for COVID-19.

 

The UK-RTC, which was announced by the UK Government yesterday, comprises Omega, Abingdon Health Limited, BBI Solutions Limited, CIGA Healthcare Limited, and the University of Oxford (the "Parties") and was formed at the request of the UK Government to support the development and manufacturing scale-up of a COVID-19 lateral flow antibody test ("COVID-19 Rapid Test") to determine whether people have developed immunity after contracting the virus.

 

The MOU is for an initial period of six months and the Parties will collaborate to utilise their combined lateral flow test design and manufacturing expertise to optimise the design for potential accelerated scale-up to manufacturing of the COVID-19 Rapid Test.

 

Once the COVID-19 Rapid Test reaches design freeze, then the specification and standard operating procedures will be shared with each party of the consortium to enable manufacturing and/or assembly to be undertaken at each site, including at Omega's manufacturing facility in Alva, Scotland, according to capability.

 

Colin King, CEO of Omega commented: "We are delighted to be part of this consortium and to support the Scottish and UK Governments' efforts to combat the Coronavirus pandemic and look forward to using Omega's manufacturing knowledge and capabilities in supporting and furthering this objective."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Contacts: 

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

Bill Rhodes, Interim Non-Executive Chairman

Colin King, Chief Executive

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Hannah Boros (Corporate Finance)

Camille Gochez (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSSSESAESSEDL
Date   Source Headline
4th Jan 20224:36 pmRNSPrice Monitoring Extension
14th Dec 20217:00 amRNSConfirmation of detection of Omicron variant
10th Dec 20212:06 pmRNSSecond Price Monitoring Extn
10th Dec 20212:01 pmRNSPrice Monitoring Extension
10th Dec 20219:30 amRNSDHSC contract update
1st Dec 20214:40 pmRNSSecond Price Monitoring Extn
1st Dec 20214:35 pmRNSPrice Monitoring Extension
1st Dec 20212:05 pmRNSSecond Price Monitoring Extn
1st Dec 20212:00 pmRNSPrice Monitoring Extension
26th Nov 20212:06 pmRNSSecond Price Monitoring Extn
26th Nov 20212:00 pmRNSPrice Monitoring Extension
25th Nov 20219:06 amRNSSecond Price Monitoring Extn
25th Nov 20219:00 amRNSPrice Monitoring Extension
25th Nov 20217:00 amRNSHalf-year Report
5th Nov 20217:00 amRNSNotice of Results and Investor Presentation
3rd Nov 20217:00 amRNSUpdate on CTDA Regulations
1st Nov 20213:28 pmRNSExercise of Options and Total Voting Rights
1st Nov 20217:00 amRNSPartnership with DAM Health and initial LFT order
19th Oct 202112:00 pmRNSExercise of Options and Total Voting Rights
15th Sep 20213:26 pmRNSResult of AGM
15th Sep 20217:00 amRNSAGM Statement
30th Jul 202112:35 pmRNSPosting of Annual Report & Accounts &Notice of AGM
27th Jul 20217:00 amRNSAbC-19 monitors vaccine response to variants
13th Jul 20217:01 amRNSFinal Results
13th Jul 20217:00 amRNSDirectorate Change
9th Jul 20219:08 amRNSAbC-19 rapid antibody test performance evaluation
2nd Jul 20217:00 amRNSFDA submission for Emergency Use Authorization
16th Jun 20217:00 amRNSNotice of Results
15th Jun 202110:49 amRNSStatement re. Media Comment
10th Jun 20212:05 pmRNSSecond Price Monitoring Extn
10th Jun 20212:00 pmRNSPrice Monitoring Extension
8th Jun 20217:00 amRNSRegulatory progress for VISITECT® COVID-19 test
7th Jun 20217:00 amRNSProgress update
1st Jun 20217:00 amRNSPositive data for COVID-19 antigen test
6th May 20214:41 pmRNSSecond Price Monitoring Extn
6th May 20214:35 pmRNSPrice Monitoring Extension
5th May 20217:00 amRNSPositive data for Mologic COVID-19 antigen test
30th Apr 20211:30 pmRNSExercise of Options and Total Voting Rights
30th Apr 20217:00 amRNSLaunch of VISITECT® COVID-19 Antigen & Update
23rd Apr 202110:30 amRNSDirector/PDMR Shareholding and Total Voting Rights
19th Apr 20217:00 amRNSDirector/PDMR Shareholding
31st Mar 202112:31 pmRNSDirector/PDMR Shareholding and Total Voting Rights
26th Mar 20215:36 pmRNSExercise of Options and Total Voting Rights
26th Mar 20214:40 pmRNSSecond Price Monitoring Extn
26th Mar 20214:35 pmRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSCE-Mark: Mologic COVID19 lateral flow antigen test
19th Mar 20211:15 pmRNSExercise of Options and Total Voting Rights
15th Mar 20215:28 pmRNSStatement re. Government press release
15th Mar 20217:00 amRNSUK Public Sector Contract disclosure
8th Mar 20217:00 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.